• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4-disubstituted thiazoles

Recent Advances in the Study of 4-Phenyl-2-(m-tolyl)thiazole (CAS: 2227-70-5) in Chemical Biology and Pharmaceutical Research

The compound 4-Phenyl-2-(m-tolyl)thiazole (CAS: 2227-70-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This thiazole derivative, characterized by a phenyl and m-tolyl substituent, has been the subject of numerous studies aimed at exploring its biological activities, mechanism of action, and potential as a drug candidate. The following research brief synthesizes the latest findings related to this compound, providing a comprehensive overview of its current status in scientific research.

Recent studies have focused on the synthesis and optimization of 4-Phenyl-2-(m-tolyl)thiazole to enhance its pharmacological properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that modifications to the thiazole core structure could significantly improve its binding affinity to target proteins, particularly those involved in inflammatory pathways. The researchers employed computational docking studies and molecular dynamics simulations to predict the compound's interactions with cyclooxygenase-2 (COX-2), a key enzyme in inflammation. Subsequent in vitro assays confirmed these predictions, showing potent inhibition of COX-2 activity at nanomolar concentrations.

In addition to its anti-inflammatory potential, 4-Phenyl-2-(m-tolyl)thiazole has shown promise as an anticancer agent. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that this compound exhibits selective cytotoxicity against certain cancer cell lines, including breast and lung adenocarcinoma. The study highlighted the compound's ability to induce apoptosis via the mitochondrial pathway, as evidenced by increased caspase-3 activity and cytochrome c release. Furthermore, the researchers observed synergistic effects when 4-Phenyl-2-(m-tolyl)thiazole was combined with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy.

The pharmacokinetic profile of 4-Phenyl-2-(m-tolyl)thiazole has also been a subject of investigation. A recent preclinical study evaluated the compound's absorption, distribution, metabolism, and excretion (ADME) properties in rodent models. The results indicated favorable oral bioavailability and a half-life suitable for once-daily dosing. However, the study also identified potential metabolic liabilities, particularly cytochrome P450-mediated oxidation, which may necessitate further structural optimization to improve metabolic stability.

Beyond its therapeutic applications, 4-Phenyl-2-(m-tolyl)thiazole has been explored as a chemical probe for studying biological systems. Its fluorescent properties, attributed to the conjugated thiazole system, make it a valuable tool for imaging studies. A 2023 publication in Chemical Communications detailed the development of a 4-Phenyl-2-(m-tolyl)thiazole-based fluorescent probe for real-time monitoring of intracellular reactive oxygen species (ROS) levels. The probe demonstrated high sensitivity and selectivity for ROS, enabling researchers to visualize oxidative stress dynamics in live cells.

In conclusion, the growing body of research on 4-Phenyl-2-(m-tolyl)thiazole (CAS: 2227-70-5) underscores its multifaceted potential in chemical biology and pharmaceutical development. From its promising therapeutic activities to its utility as a research tool, this compound continues to reveal new opportunities for scientific exploration. Future studies will likely focus on addressing its metabolic challenges and expanding its applications in targeted drug delivery and diagnostic imaging. As research progresses, 4-Phenyl-2-(m-tolyl)thiazole may emerge as a valuable scaffold for the development of novel bioactive molecules.

• 1826-17-1(4-Methyl-2-phenylthiazole)
• 2362-58-5(4-(4-methylphenyl)-2-phenyl-1,3-thiazole)
• 1826-16-0(2-Methyl-4-phenylthiazole)
• 66047-73-2(2-methyl-4-(4-methylphenyl)-1,3-thiazole)
• 24864-19-5(4-(4-Biphenylyl)-2-methyl-1,3-thiazole)
• 25021-48-1(4-(2-PHENYL-1,3-THIAZOL-4-YL)ANILINE)
• 2227-61-4(4-Phenyl-2-(p-tolyl)thiazole)
• 1826-14-8(Thiazole, 2,4-diphenyl-)
• 25179-47-9(Benzenamine, 4-[2-(4-methylphenyl)-4-thiazolyl]-)
• 106950-18-9(4-Phenyl-2-(4-pyridyl)thiazole, 97%)